Our project demonstrates the successful collaboration between ICS (Surrey Heartlands) and the NHS Trust (Royal Surrey NHS Foundation Trust) in enhancing medicines optimization and achieving more efficient prescribing practices within the local system. Through the implementation of a redesigned local pathway for wet age-related macular degeneration (wet AMD) and Diabetic Macular Oedema (DMO) and prioritizing the use of biosimilar ranibizumab as the primary treatment option, we have observed a significant reduction in costs based on the initial two months of data collection (April and May 2023). The ongoing project provides the best possible value for our Tax payers and allows for more efficient utilization of resources without compromising outcomes. It aligns with the Trust and System core values of continuous improvement and supports the attainment of high standards.
We sincerely appreciate your consideration of our application and the opportunity to share our success story. Our project embodies the spirit of collaborative working, innovation, and the pursuit of excellence. We believe it exemplifies the values and objectives of the Integrated/Joint Working category and stands as a testimony to the transformative power of medicines optimization.
Thank you for your time and consideration.
